Please select the option that best describes you:
Topics:
Breast Cancer • Medical Oncology • HER2+ • Targeted therapies • Journal Club ft. NEJM publications • Breast Cancer, Metastatic
What are the recommended second-line treatment options for patients with metastatic HER2+ breast cancer who have received frontline trastuzumab deruxtecan (T-DXd)?
Should a taxane-based regimen be considered, or would the HER2CLIMB regimen be more appropriate?
Answer from: Medical Oncologist at Academic Institution
There is currently limited direct evidence to guide optimal sequencing after frontline trastuzumab deruxtecan, so second-line treatment decisions are individualized. In many cases, the HER2CLIMB regimen with tucatinib, capecitabine, and trastuzumab is an appealing option, particularly for patients w...
Sign In or Register to read more
Answer from: Medical Oncologist at NCI-Designated Cancer Center
There are no clinical trial-level data to guide us on this, but in my practice, I would consider going to THP as a second-line if the patient is a good candidate at that point. For patients with CNS metastases progressing on T-DXd, I would likely move on to the HER2CLIMB regimen with capecitabine, t...